Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b).

ABSTRACT:

Background

We analyzed the early kinetics with integrase inhibitor treatment to gain new insights into viral dynamics.

Methodology

We analyzed data from 39 HIV-1 infected, treatment-naive, participants: 28 treated with raltegravir (RAL; multiple doses) monotherapy for 9 days, and 11 with RAL 400 mg twice daily and emtricitabine (200 mg daily)/tenofovir disoproxil fumarate (300 mg daily). Plasma HIV-1 RNA was measured frequently; the data was fitted using a mathematical model of viral dynamics distinguishing between infected cells with unintegrated HIV DNA and productively infected cells. Parameters were estimated using mixed-effect models.

Results

RAL treatment led to a biphasic viral decline with a rapid first phase (1a) lasting approximately 5 days followed by a slo

SUBMITTER: Andrade A 

PROVIDER: S-EPMC4646723 | biostudies-literature | 2015 Nov

REPOSITORIES: biostudies-literature